TrialPath
Recruiting

Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

NCT04874012 · Hospital de Clinicas de Porto Alegre
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial
About this study
A randomized, double-blind, placebo-controlled clinical trial will be conducted at Hospital de Clínicas de Porto Alegre (HCPA), Brazil. A total of 94 participants with DM2 will be recruited and randomized on a 1:1 ratio to receive 3 g taurine as a powder for oral suspension, twice per day, for 12 weeks or packets containing placebo. Blood will be collected prior to the treatment and after 12 weeks for glycated hemoglobin, fasting glucose, insulinemia, total cholesterol and fractions, triglycerides, C-reactive protein, creatinine, urea, tumor necrosis factor-alpha (TNF-α), interleukin 1 and 6 (IL-1 and IL-6) measures. Urine will be collected at baseline and after 12 weeks for creatine, protein, and albumin measured. Anthropometric parameters and a 24-h dietary recall will be monthly investigated. Fourteen days before the end of the trial, participants will be connected to a continuous glucose monitoring system for glucose monitoring system for glucose variability evaluation. Participants will be contacted by phone weekly to report adverse effects.
Eligibility criteria
Inclusion criteria * Female and male individuals, with clinical diagnosis of DM2 for at least 6 months; * Age over 30 years; * BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months; * HbA1c between 7.5% and 10.5%. Exclusion criteria * Use of herbal supplements, antioxidants, and multivitamins in the last 3 months; * Pregnancy or lactation; * Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h; * Myocardial infarction in the last than 6 months * Current neoplasia; * Chronic use of glucocorticoids; * Bariatric surgery.
Study design
Enrollment target: 94 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2021-06-12
Estimated completion: 2026-12-01
Last updated: 2026-09-24
Interventions
Drug: Active comparator TaurineOther: Placebo Comparator
Primary outcomes
  • • HbA1c (baseline and 12 weeks)
Sponsor
Hospital de Clinicas de Porto Alegre · other
Contacts & investigators
ContactBeatriz D Schaan, PhD · contact · bschaan@hcpa.edu.br · 55 51 3359-8000
ContactRosane Gomez, PhD · contact · rogomez@hcpa.edu.br · 55 51 33082823
InvestigatorBeatriz D Schaan, PhD · principal_investigator, Hospital de Clinicas de Porto Alegre
All locations (1)
Hospital de ClínicasRecruiting
Porto Alegre, Rio Grande do Sul, Brazil
Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes · TrialPath